durcabtagene autoleucel

Durcabtagene autoleucel (also known as PHE885) is an autologous B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Novartis Pharmaceuticals. It was designed for the treatment of relapsed and refractory multiple myeloma. The therapy utilizes Novartis's T-Charge platform, which aims to reduce ex-vivo manufacturing time to less than two days, enhance in-vivo expansion, and preserve T-cell stemness, potentially leading to more potent and durable responses. It works by genetically engineering a patient's own T-cells to express a CAR that specifically targets BCMA, a protein overexpressed on malignant plasma cells, leading to selective toxicity against these cancer cells.

Other names

Anti-BCMA CAR-T Cell Therapy - Novartis PharmaceuticalsBCMA-directed CAR-T Cell Therapy